全文获取类型
收费全文 | 68篇 |
免费 | 1篇 |
专业分类
管理学 | 5篇 |
民族学 | 2篇 |
人口学 | 4篇 |
理论方法论 | 46篇 |
综合类 | 2篇 |
社会学 | 9篇 |
统计学 | 1篇 |
出版年
2021年 | 1篇 |
2020年 | 1篇 |
2019年 | 1篇 |
2017年 | 2篇 |
2016年 | 1篇 |
2015年 | 1篇 |
2013年 | 29篇 |
2012年 | 2篇 |
2011年 | 1篇 |
2008年 | 2篇 |
2007年 | 1篇 |
2006年 | 4篇 |
2005年 | 1篇 |
2004年 | 1篇 |
2003年 | 3篇 |
2002年 | 3篇 |
2000年 | 1篇 |
1999年 | 3篇 |
1998年 | 1篇 |
1997年 | 1篇 |
1996年 | 3篇 |
1993年 | 2篇 |
1992年 | 2篇 |
1991年 | 1篇 |
1968年 | 1篇 |
排序方式: 共有69条查询结果,搜索用时 890 毫秒
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
The use of drugs for indications unapproved by the Food and Drug Administration (FDA), often called "off label use, "is widespread in children, including neonates. The widespread off-label use of drugs in neonates presents ethical and safety challenges. Since the passage of the Best Pharmaceuticals for Children Act (BPCA) in 2002, both the FDA and National Institutes of Health (NIH) have taken initiatives to facilitate and encourage research to achieve the necessary labeling for drugs routinely used in infants and children. Federal regulations provide broad rules and guidance for the protection of human subjects in research. However, there are ethical issues that a physician may face when designing clinical trials of drugs in neonates that are routinely used off-label and widely believed to be beneficial. We attempt to describe these ethical challenges and provide recommendations, including alternative study designs, to resolve them in an ethical framework that takes into account the Belmont Report, the statement of the World Medical Association (WMA), and federal regulations. 相似文献